pl
en
Country
pl
Language
en
Janssen.tv Janssen.tv MENU

HIV eradication possibilities

Speciality: Infectious diseases
Language : Polski
Date: June 23, 2015

Department of Infectious Diseases, Tropical and Acquired Immunodeficiency Immune, Pomeranian Medical University

Lecturers

Miłosz Parczewski, MD, Ph.D
Infectious diseases, Genetics Miłosz Parczewski, MD, Ph.D Poland Department of Infectious Diseases, Tropical Diseases and Acquired Immunodeficiency

Other in: Infectious diseases

The future of HIV infection therapy
Infectious diseases Open broadcast The future of HIV infection therapy Miłosz Parczewski, MD, Ph.D
PL
Case study: own experience in the three-drug therapy using telaprevir in hepatitis C patients.
Infectious diseases Open broadcast Case study: own experience in the three-drug therapy using telaprevir in hepatitis C patients. Maciej Jabłkowski, MD, Ph.D
Dr Dorota Dybowska,
Ewa Janczewska, MD, Ph.D
PL
Debate: Why shouldn't patients wait for a three-drug therapy?
Infectious diseases Open broadcast Debate: Why shouldn't patients wait for a three-drug therapy? Prof. Anna Boroń-Kaczmarska, MD, Ph.D
Jerzy Jaroszewicz, MD, Ph.D
Ewa Janczewska, MD, Ph.D
PL
Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 3: Others
Infectious diseases Open broadcast Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 3: Others Several lecturers
PL
Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 2: Rash
Infectious diseases Open broadcast Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 2: Rash Several lecturers
PL
Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 1: Anemia
Infectious diseases Open broadcast Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 1: Anemia Several lecturers
PL
Initial efficacy and safety assessment of telaprevir in combination with interferon and ribaviryn in a Polish cohort of patients with advanced liver fibrosis and cirrhosis
Infectious diseases Live conference Initial efficacy and safety assessment of telaprevir in combination with interferon and ribaviryn in a Polish cohort of patients with advanced liver fibrosis and cirrhosis Ewa Janczewska, MD, Ph.D
PL
Trial design of the impact of modified RBV doses on the efficacy of triple therapy with telaprevir in patients infected with 1 HCV genotype with advanced liver fibrosis with prior treatment failure
Infectious diseases Live conference Trial design of the impact of modified RBV doses on the efficacy of triple therapy with telaprevir in patients infected with 1 HCV genotype with advanced liver fibrosis with prior treatment failure Prof. Robert Flisiak, MD, Ph.D
PL
Telaprevir in Polish clinical practice
Infectious diseases Live conference Telaprevir in Polish clinical practice Dr Hanna Berak,
PL
Telaprevir in Polish clinical practice
Infectious diseases Live conference Telaprevir in Polish clinical practice Dr Beata Dobracka,
PL
Telaprevir in Polish clinical practice
Infectious diseases Live conference Telaprevir in Polish clinical practice Ewa Janczewska, MD, Ph.D
PL
Telaprevir in Polish clinical practice
Infectious diseases Live conference Telaprevir in Polish clinical practice Dr Dorota Kozielewicz,
PL
Telaprevir in Polish clinical practice
Infectious diseases Live conference Telaprevir in Polish clinical practice Prof. Tadeusz W. Łapiński, MD, Ph.D
PL
Telaprevir in Polish clinical practice
Infectious diseases Live conference Telaprevir in Polish clinical practice Dorota Zarębska-Michaluk, MD, Ph.D
PL